Company Overview - LifeMD (NASDAQ: LFMD) is a rapidly growing telehealth company that provides subscriptions and prescriptions for chronic conditions [1] - The company has 290,000 active patient subscribers and operates across all 50 states in the United States [1] Business Model - LifeMD's business model focuses on telehealth services, which include both subscription-based and prescription services [1] Market Position - LifeMD is positioned in the telehealth industry, which is experiencing significant growth due to increasing demand for remote healthcare solutions [1]

SAN DIEGO, June 25, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”), have until August 25, 2025 to seek appointment as lead plaintiff of the Hims & Hers class action lawsuit. Captioned Sookdeo v. Hims & Hers Health, Inc., No. 25-cv-05315 (N.D. Cal.), the Hims & Hers class action lawsuit charges Hims & Hers and certain of Hims & Hers’ to ...

Core Viewpoint - Hims & Hers Health, Inc. experienced a significant share price drop of over 30% following the termination of its collaboration with Novo Nordisk due to concerns regarding sales practices and marketing of the weight loss drug Wegovy® [1][4]. Company Summary - Hims & Hers Health, Inc. had previously partnered with Novo Nordisk to provide access to Wegovy®, which is FDA-approved for obesity treatment, through its platform [3]. - The partnership was short-lived, as Novo Nordisk cited "illegal mass compounding and deceptive marketing" as reasons for the termination [4]. - Hims & Hers had previously assured investors of its regulatory compliance, claiming it was not bypassing the regulatory process [2]. Investigation Summary - Hagens Berman, a national shareholders rights firm, has initiated an investigation into potential violations of securities laws by Hims & Hers, urging affected investors to report their losses [2]. - The investigation will focus on whether Hims & Hers misled investors regarding the marketing of potentially unsafe versions of Wegovy® [4].

Core Viewpoint - The Schall Law Firm is investigating Hims & Hers Health, Inc. for potential violations of securities laws following a significant drop in share price due to allegations of illegal practices and misleading marketing [1][2]. Group 1: Investigation Details - The investigation centers on whether Hims & Hers made false or misleading statements and failed to disclose critical information to investors [2]. - Novo Nordisk announced the termination of its relationship with Hims & Hers due to concerns over illegal mass compounding and deceptive marketing practices [2]. - Following the announcement from Novo Nordisk, Hims & Hers shares plummeted by over 32.4% in afternoon trading [2]. Group 2: Company Background - Hims & Hers Health, Inc. is involved in telehealth services and has faced scrutiny regarding its compliance with laws governing the sale of compounded drugs [2]. - The FDA has resolved a shortage of Wegovy® and confirmed that Novo Nordisk is meeting the demand, which has implications for Hims & Hers' business practices [2].

Core Viewpoint - Hims & Hers Health Inc experienced a significant stock decline of 34% following the termination of its relationship with Novo Nordisk, raising questions about the future of the company amidst regulatory challenges and market dynamics [1]. Company Overview - Hims & Hers is a high-growth telehealth firm that provides a range of health products, including hair loss medications and mental health prescriptions [1]. - The company generated approximately $200–225 million in 2024 from its GLP-1 business, which constituted a substantial portion of its projected $1.48 billion revenue [4]. Regulatory Challenges - The FDA's recent declaration that supply shortages are resolved has rendered compounded GLP-1 alternatives illegal, leading to accusations from Novo Nordisk against Hims for ignoring regulatory compliance [2]. - Novo Nordisk's actions signal a broader regulatory scrutiny within the telehealth industry, indicating potential challenges for companies operating in this space [4]. Financial Metrics - Hims is currently trading at a forward P/E ratio of 69.4, which is over 2.5 times the sector median, and a PEG ratio of 3.9, suggesting that the current valuation may be difficult to justify without significant earnings growth [3]. - The stock has seen a year-to-date decline of 66% and is trading below its eight, 20, and 50-day moving averages, with an RSI of 38.69, indicating it is nearing oversold conditions [6]. Market Position and Future Outlook - Despite the challenges, over 80% of Hims' revenue is derived from non-weight-loss verticals, such as acne and anxiety treatments, which are expected to remain stable [5]. - The company is recognized as a leading direct-to-consumer health brand among millennials and Gen Z, which may provide a foundation for future growth [5]. - The MACD indicator is currently positive at 0.48, suggesting a potential bullish signal, while the stock remains above the 200-day moving average, indicating some long-term trend support [7].

NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Hims & Hers Health, Inc. (NYSE: HIMS) for potential violations of the federal securities laws. If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action. Why is Hims & Hers being Investigated? Hims & Hers is a telehealth company that provides consumers access to ...

SAN DIEGO, June 23, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Hims & Hers Health, Inc. (NYSE: HIMS) focused on whether Hims & Hers and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors.If you have information that could assist in the Hims & Hers investigation or if you are a Hims & Hers investor who suffered a loss and would like to learn ...

SAN FRANCISCO, June 23, 2025 (GLOBE NEWSWIRE) -- On June 23, 2025 investors in Hims & Hers Health, Inc. (NYSE: HIMS) saw the price of their shares crash over 30% after Novo Nordisk announced that it terminated its collaboration with the telehealth company due to concerns about Hims & Hers’ sales and “deceptive” marketing of the weight loss drug Wegovy®. This news has prompted national shareholders rights firm Hagens Berman to open an investigation into possible violations of the securities laws. The firm ur ...

BOSTON, June 23, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Hims & Hers Health, Inc. (NYSE: HIMS) for potential securities law violations. Investors who have lost money in their Hims & Hers Health, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/hims. What is this all about? Shares of Hims & Hers Health fell over 25% on June 23 after Novo Nordisk announced it was terminating its partnership ...

Core Viewpoint - Mobile-health Network Solutions (MNDR) is transitioning to a leaner, asset-light model focused on AI-driven virtual care, aiming for scalability and profitability despite short-term revenue declines due to the closure of its CityGate clinic in Singapore [2][3]. Financial Performance - For H1 FY2025, MNDR reported revenue of US$4.3 million, down from US$6.6 million in H1 FY2024, and a net loss of US$(1.7 million) compared to US$(1.5 million) in the same period last year [7]. - Cash and cash equivalents decreased to US$2.6 million from US$6.7 million in H1 FY2024 [7]. Strategic Initiatives - The closure of the CityGate clinic is seen as a pivotal moment in the company's transformation towards a globally scalable, AI-focused platform [3]. - In April 2025, MNDR acquired Lifepack, enhancing its telehealth and pharmacy services for Indonesia's 280 million people, many of whom are underserved [4]. - The company secured US$10 million in funding in January 2025 to advance its AI-driven healthcare solutions, including the AI Agent platform [5]. Operational Developments - MNDR has integrated AI agents into its MaNaDr app to reduce operational costs while improving care and service delivery [8]. - The launch of AI Notes in March 2025 automates clinical note-taking for doctors, enhancing efficiency [11]. - A tele-dentistry service was announced in May 2025, allowing patients to perform AI-enhanced dental scans at home [11]. Future Outlook - The company anticipates that recent initiatives will lead to higher revenue and aims to achieve breakeven by H2 FY2025 and profitability before H1 FY2027 [9].